Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29559150 | 1.00 | HTR2A (0.33) | HTR2AHTR2CHTR2BCYP1A2CYP2A6 | |
| SCHEMBL6952377 | 0.85 | HTR2A (0.33) | HTR2AHTR2CHTR2B | |
| SCHEMBL24946159 | 0.81 | CYP1A2 (0.34) | CYP1A2CYP2A6 | |
| SCHEMBL24946157 | 0.81 | CTRC (0.37) | — | |
| SCHEMBL30200221 | 0.81 | CYP1A2 (0.34) | CYP1A2CYP2A6 | |
| SCHEMBL21625583 | 0.78 | HTR2A (0.37) | HTR2AHTR2CHTR2B | |
| SCHEMBL24947185 | 0.78 | HTR2C (0.30) | HTR2C | |
| SCHEMBL30538828 | 0.78 | — | — | |
| SCHEMBL29559422 | 0.78 | HTR2C (0.30) | HTR2C | |
| SCHEMBL24947655 | 0.77 | HTR2A (0.33) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) | 2025-04-03 | — | — | US | disclosed |
| WO-2024041609-A1 | BENZO BICYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 广州市联瑞制药有限公司 | 2024-02-29 | — | — | WO | disclosed |
| WO-2023000834-A1 | BENZIMIDAZOLE OR AZABENZIMIDAZOLE-6-CARBOXYLIC ACID COMPOUND AND USE THEREOF | 广州必贝特医药股份有限公司 | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | HTR2A 134/4885HTR2C 152/4885HTR2B 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.